TY - JOUR
T1 - Combination drug therapy
AU - Tangalos, Eric G.
AU - Zarowitz, Barbara J.
N1 - Funding Information:
We thank CERN for the very successful operation of the LHC, as well as the support staff from our institutions without whom ATLAS could not be operated efficiently. We acknowledge the support of ANPCyT, Argentina; YerPhI, Armenia; ARC, Australia; BMWFW and FWF, Austria; ANAS, Azerbaijan; SSTC, Belarus; CNPq and FAPESP, Brazil; NSERC, NRC and CFI, Canada; CERN; CONICYT, Chile; CAS, MOST and NSFC, China; COLCIENCIAS, Colombia; MSMTCR, MPOCR and VSC CR, Czech Republic; DNRF, DNSRC and Lundbeck Foundation, Denmark; IN2P3-CNRS, CEADSM/ IRFU, France; GNSF, Georgia; BMBF, HGF, and MPG, Germany; GSRT, Greece; RGC, Hong Kong SAR, China; ISF, I-CORE and Benoziyo Center, Israel; INFN, Italy; MEXT and JSPS, Japan; CNRST, Morocco; FOM and NWO, Netherlands; RCN, Norway; MNiSW and NCN, Poland; FCT, Portugal; MNE/IFA, Romania; MES of Russia and NRC KI, Russian Federation; JINR; MESTD, Serbia; MSSR, Slovakia; ARRS and MIZ?, Slovenia; DST/NRF, South Africa; MINECO, Spain; SRC and Wallenberg Foundation, Sweden; SERI, SNSF and Cantons of Bern and Geneva, Switzerland; MOST, Taiwan; TAEK, Turkey; STFC, United Kingdom; DOE and NSF, United States of America. In addition, individual groups and members have received support from BCKDF, the Canada Council, CANARIE, CRC, Compute Canada, FQRNT, and the Ontario Innovation Trust, Canada; EPLANET, ERC, FP7, Horizon 2020 and Marie Sk?odowska-Curie Actions, European Union; Investissements d?Avenir Labex and Idex, ANR, Region Auvergne and Fondation Partager le Savoir, France; DFG and AvH Foundation, Germany; Herakleitos, Thales and Aristeia programmes co-financed by EU-ESF and the Greek NSRF; BSF, GIF and Minerva, Israel; BRF, Norway; the Royal Society and Leverhulme Trust, United Kingdom. The crucial computing support from all WLCG partners is acknowledged gratefully, in particular from CERN and theATLAS Tier- 1 facilities at TRIUMF (Canada), NDGF (Denmark, Norway, Sweden), CC-IN2P3 (France), KIT/GridKA (Germany), INFN-CNAF (Italy), NL-T1 (Netherlands), PIC (Spain), ASGC (Taiwan), RAL (UK) and BNL (USA) and in the Tier-2 facilities worldwide.
PY - 2005
Y1 - 2005
N2 - Our job as practitioners, pharmacists, and medical directors is to keep tasks as simple and error free as possible, not only for the patient but also for the health care team. The fewer and the more effective the therapies, the safer and the more compliant it will be for the patient, family, or direct care staff. As each of us measures the new opportunities for drug management and the ever-increasing burden of illness borne by our patients, we must be mindful of the pitfalls of drug misadventure. Our job is to first and foremost watch out for our patients, reduce errors, and keep these frail and vulnerable individuals out of the hospital. Combination drug therapy may reduce costs, provide broader treatment of disease states, and improve compliance. In long-term care settings there is even the potential that it may reduce errors.
AB - Our job as practitioners, pharmacists, and medical directors is to keep tasks as simple and error free as possible, not only for the patient but also for the health care team. The fewer and the more effective the therapies, the safer and the more compliant it will be for the patient, family, or direct care staff. As each of us measures the new opportunities for drug management and the ever-increasing burden of illness borne by our patients, we must be mindful of the pitfalls of drug misadventure. Our job is to first and foremost watch out for our patients, reduce errors, and keep these frail and vulnerable individuals out of the hospital. Combination drug therapy may reduce costs, provide broader treatment of disease states, and improve compliance. In long-term care settings there is even the potential that it may reduce errors.
UR - http://www.scopus.com/inward/record.url?scp=28744456436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28744456436&partnerID=8YFLogxK
U2 - 10.1016/j.jamda.2005.04.013
DO - 10.1016/j.jamda.2005.04.013
M3 - Article
C2 - 16286063
AN - SCOPUS:28744456436
SN - 1525-8610
VL - 6
SP - 406
EP - 409
JO - Journal of the American Medical Directors Association
JF - Journal of the American Medical Directors Association
IS - 6
ER -